Foghorn Therapeutics enters the back half of May with momentum firmly against it — a Q1 revenue miss triggered a 14.6% weekly decline, and the stock now trades at $3.79, down more than 20% over the past month.
The Q1 print, released May 7, was the root of the damage. EPS came in at -$0.29, broadly in line, but revenue of $3.3 million badly missed the $7.4 million estimate. The market responded instantly: the stock fell 5.1% on the day and lost a further 13.7% over the following five sessions. That reaction followed a pattern already visible in recent quarters — a March event saw the stock drop 10.4% on the day and 11.1% over five days. The directional consistency of these post-print moves is notable. Close peer TWST tracked a similar week, dropping 13.5%, while MRNA fell 9.8% over the same period, suggesting some sector-level pressure compounded the FHTX-specific miss.
Short positioning and borrowing costs tell a less alarming story than the price action implies. Short interest nudged up 7.7% on the week to 2.3% of free float — a modest level that lacks the conviction of a genuine bear thesis. Cost to borrow eased to 0.46%, roughly half its level a month ago, and availability remains wide. Far from signalling a crowded short trade, the lending market is relaxed. Options positioning reinforces that read: the put/call ratio is essentially at the 52-week low of 0.056, running slightly below its 20-day average. That's near the least defensive options configuration of the past year, which is a notable contrast to the week's price losses.
The Street remains constructive but cautious. Analyst coverage from Wedbush, HC Wainwright, and Jefferies all maintained Buy or Outperform ratings following the Q4/Q1 results cycle, with price targets clustered in the $10–$13 range. Note that the consensus mean target of approximately $11.44 dates to February and has not been formally refreshed since the May earnings miss, so that gap to the current $3.79 price should be treated with caution until analysts revise post-print. Jefferies trimmed its target from $14 to $12 in February. No bellwether firms have published fresh views since. The factor picture is equally uninspiring: EPS momentum ranks in the 20th percentile on a 30-day basis, and the dividend score sits at 32 — both consistent with a company burning cash in early-stage clinical development. The short score itself is a middling 47.9, drifting modestly higher through the week without reaching territory that typically flags an inflection.
Ownership gives the story an interesting structural anchor. Flagship Pioneering holds 21.6% of shares. Eli Lilly owns 4% as a strategic partner — the bear case centres on exactly how that relationship evolves, given FHD-909 is in Phase 1 and trial data remains undisclosed. FMR (Fidelity) added 1.4 million shares in Q1 to reach 11.6%, and Columbia Management picked up 495,000 shares in the same period. Active institutional buying while the stock was more elevated suggests those holders are now sitting on material drawdowns. Dana-Farber Cancer Institute also filed a new clinical trial to study Foghorn's SMARCA4/2 inhibitor for POU2F3-positive small-cell lung cancer, listed May 11 — a datapoint that provides ongoing scientific validation but no near-term commercial catalyst. The company announced participation in three investor conferences in May, signalling management remains active on the road.
The next formal event on the calendar is June 24 earnings. Given that the last three quarterly prints all produced immediate negative price reactions, and analysts have yet to revise targets post the Q1 miss, those conference appearances in the coming weeks represent the clearest near-term window in which any incremental pipeline narrative could either arrest or extend the current slide.
See the live data behind this article on ORTEX.
Open FHTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
